N
Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, and Shanghai.
Investor insights
Funding rounds participated in
$150M sweet spot round size
Investor type
Public Company
Basic info
Industry
Pharmaceutical Manufacturing
Sectors
Pharmaceutical Manufacturing
Date founded
2018
Funding rounds raised
Total raised
$150M
from 1 investors over 1 rounds
N
Nuvation Bio raised $150M on April 3, 2025
Investors: Sagard Healthcare Royalty Partners